Zentalis Pharmaceuticals, Inc. (ZNTL)
NASDAQ: ZNTL · Real-Time Price · USD
4.000
-0.090 (-2.20%)
At close: May 4, 2026, 4:00 PM EDT
4.100
+0.099 (2.49%)
After-hours: May 4, 2026, 7:55 PM EDT
Zentalis Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
106
Market Cap
283.72M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 67.43M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cellectis | 79.59M |
| Coherus Oncology | 42.17M |
| Editas Medicine | 40.52M |
| C4 Therapeutics | 35.95M |
| Foghorn Therapeutics | 30.91M |
| LENZ Therapeutics | 19.09M |
| AC Immune | 4.62M |
ZNTL News
- 3 days ago - Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 13 days ago - Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer - GlobeNewsWire
- 17 days ago - Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026 - GlobeNewsWire
- 24 days ago - What's Behind The Surge In Zentalis Stock? - Benzinga
- 25 days ago - Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer - GlobeNewsWire
- 4 weeks ago - Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates - GlobeNewsWire
- 6 weeks ago - Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026 - GlobeNewsWire